Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar
Esmée J Grobbee, Vivian D de Jong, Ilse C Schrieks, Maarten E Tushuizen, Adriaan G Holleboom, Jean-Claude Tardif, A Michael Lincoff, Gregory G Schwartz, Manuel Castro Cabezas, Diederick E Grobbee
Research output: Contribution to journal › Article › Academic › peer-review
12Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar'. Together they form a unique fingerprint.